文献速递头颈神经CTMRPET

NI-RADS初始性能:预测头颈部鳞状细胞癌残留或复发

Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-03-31

本研究为质量改进项目,回顾性分析500例连续病例中符合纳入标准的318次扫描和618个靶点(314个原发灶靶点、304个淋巴结靶点),评估NI-RADS评分系统预测局部和区域疾病复发或持续存在的性能。618个靶点中85.4%评为NI-RADS 1、9.4%评为NI-RADS 2、5.2%评为NI-RADS 3,各分类阳性率分别为3.79%、17.2%、59.4%;单因素分析显示NI-RADS评分与原发和区域最终疾病复发强相关(P < .001)。结论认为NI-RADS基线性能良好,对1-3类预测疾病具有显著区分能力。

要点

  • NI-RADS 1、2、3类的阳性率分别为3.79%、17.2%、59.4%。
  • NI-RADS评分与原发和区域最终复发强相关,P < .001。
  • 618个靶点中85.4%为NI-RADS 1、9.4%为2、5.2%为3。

核心结论

  • NI-RADS基线性能良好,对1-3类预测疾病具有显著区分能力。

研究设计与样本

  • 质量改进项目,回顾性数据库检索500例连续病例,最终纳入318次扫描和618个靶点(314个原发灶靶点、304个淋巴结靶点),采用NI-RADS监测模板评分,以电子病历记录的后续处理、病理结果及临床和影像随访结局为参考。

诊断标准与关键数值

  • NI-RADS分类标准:1类为无复发证据,2类为低度怀疑复发,3类为高度怀疑复发,4类为已知复发;618个靶点中85.4%为NI-RADS 1、9.4%为NI-RADS 2、5.2%为NI-RADS 3,各类阳性率分别为3.79%、17.2%、59.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence.

MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up.

RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites.

CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Krieger DA, Hudgins PA, Nayak GK, et al. Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma. AJNR Am J Neuroradiol. 2017. PMID: 28364010. doi:10.3174/ajnr.A5157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。